Skip to content
  • Follow Us

CarboHyde

SUGAR IS LIFE

  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog
  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog

CarboHyde

SUGAR IS LIFE

  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Nov 7, 2022Tamas Sohajdadrug developmentcholesterol, clinical trial, cyclodextrin, rare disease

Cyclo Therapeutics, Inc. (Caroline Hastings, Benny Liu, Bryan Hurst, Gerald Cox and Sharon Hrynkow) Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Artikle: https://www.sciencedirect.com/science/article/pii/S109671922200419X

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Prev
Next
Developed by Shuttle Themes. Powered by WordPress.
  • Contact Us
  • LinkedIn
  • Twitter